The partnership will combine technological innovation and operational expertise to build a more efficient and patient-centered chronic disease service model, supporting the industry's shift from a narrow focus supplying medication towards more comprehensive patient support. As part of the collaboration, Tenry Pharmaceutical's innovative GLP-1 therapy, Paidakang® (派达康, injectable vipeglutide), is expected to make its nationwide debut through Fangzhou's Internet hospital platform. With years of experience in ...